Hormone Therapy Combined with Chemotherapy Increases Survival for Prostate Cancer Patients

Early results from a study funded by the National Institutes of Health (NIH) have shown that men with hormone-sensitive metastatic prostate cancer who have received a combination of the chemotherapy drug docetaxel and hormone therapy lived longer than patients who received hormone therapy alone.

The study enrolled 790 men with metastatic prostate cancer who received a form of hormone therapy known as ADT (androgen deprivation therapy). ADT reduces the levels of male hormones called androgens, which can stimulate prostate cancer cells. In addition to the hormone therapy, some men received docetaxel. Sixty-nine percent of men who received the combo chemo and hormone therapy were alive at three years compared with 52.5 percent of men who received hormone therapy alone.

Johns Hopkins Kimmel Cancer Center expert, Michael Carducci, M.D., is the Genitourinary Cancers Chair for the ECOG-ACRIN who, in collaboration with SWOG, Alliance for Clinical Trials in Oncology and NRG Oncology designed and conducted the trial known as E3805.

Further follow-up will be performed on patients with less extensive metastatic disease who participated in E3805 in order to define the effect of this treatment combination on these patients.

More information

VN:F [1.9.17_1161]
Rating: 0.0/5 (0 votes cast)
2 Comments

{ 2 comments… read them below or add one }

Comments

henry ocansey March 17, 2014 at 10:28 am

great news for prostate cancer patients, who had limited options in the past.

Reply

Jude March 14, 2014 at 9:46 pm

Very interesting comments in the hot topics of the Should we eat organic foods? I would say yes were possible. love your anti spam

Reply

Leave a Comment

You can use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Johns Hopkins Medicine does not necessarily endorse, nor does Johns Hopkins Medicine edit or control, the content of posted comments by third parties on this website. However, Johns Hopkins Medicine reserves the right to remove any such postings that come to the attention of Johns Hopkins Medicine which are deemed to contain objectionable or inappropriate content. Read our Commenting Disclaimer.

Previous post:

Next post: